跳至主要内容
临床试验/NCT02398357
NCT02398357Unknown4 期

A Zelen-design Randomized Controlled Trial of the Effect of Anticoagulation After Endoscopic Therapy in Cirrhotic Patients With Portal Vein Thrombosis

Shanghai Zhongshan Hospital1 个研究点 分布在 1 个国家目标入组 96 人开始时间: 2015年3月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
发起方
入组人数
96
试验地点
1
主要终点
Recanalization rate of PVT

研究概览

简要总结

To determine the effect and safety of anticoagulation after endoscopic therapy in cirrhotic patients with portal vein thrombosis and to explore whether it can decrease the short-term rebleeding rate.

详细描述

The treatment of cirrhotic patients with PVT (portal vein thrombosis) is clearly recommended in guideline now. Several published studies has confirm the effect and safety of anticoagulation therapy in cirrhotic patients with PVT.The present studies are most observation studies with small sample size and low quality.We need more high-quality research such as randomized controlled trials. This is a Zelen-designed randomized controlled trial. Patients will randomly enter into two groups:the anticoagulation group or the control group and then we will make sure wether their are fond of the group and make decision by themselves. The recanalization rate and complications will be analyzed

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age between 18-70 years old;
  • A clinical, radiological or histologic diagnosis of Liver cirrhosis and portal hypertension;
  • Diagnosed of Portal vein thrombosis;
  • Capable of understanding the purpose and risks of the study and informed consent to participate in the study;
  • Have undergone endoscopy to prevent variceal rebleeding.

排除标准

  • Age <18 or >70 years;
  • Portal vein thrombosis diagnosed before 6 months;
  • Patients with signs of acute PVT such as fever,abdominal pain or intestinal obstruction,who should be treated immediately;
  • Pregnant or nursing;
  • Hepatocellular carcinoma;
  • Severe cardiopulmonary diseases or concomitant renal insufficiency;
  • cavernous transformation of the portal vein;
  • Contradictions to endoscopy;
  • Contradictions to anticoagulation,such as:allergy to LMWH or warfarin, severe uncontrolled hypertension, history of hemorrhagic cerebral vascular accident, recent peptic ulcer disease, bacterial endocarditis, ulcerative colitis,sustained platelet count < 50 x103/uL);
  • Taking immunosuppressive agent;
  • Coagulation disorders other than the liver disease related;
  • Variceal bleeding failed to control.

研究组 & 干预措施

Anticoagulation

Experimental

Nadroparin Calcium and Warfarin

干预措施: Nadroparin Calcium and Warfarin (Drug)

结局指标

主要结局

Recanalization rate of PVT

时间窗: 8 weeks

Patients will receive Doppler ultrasound before enrolled and after followed up for 8 weeks

次要结局

  • Incidence rate of complications(8 weeks)
  • Rebleeding rate(8 weeks)

研究者

发起方
Shanghai Zhongshan Hospital
申办方类型
Other
责任方
Principal Investigator
主要研究者

Shiyao Chen

department of Gastroenterology

Shanghai Zhongshan Hospital

研究点 (1)

Loading locations...

相似试验